EMN15/HOVON147: Adding carfilzomib to Rd significantly improves MRD negativity rates in patients with high-risk smoldering multiple myeloma

Multiple Myeloma (MM)

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis^®)-Based Regimens in Patients with NDMM

ASH 2024

Multiple Myeloma (MM)

AQUILA: Daratumumab significantly improves PFS in high-risk smoldering multiple myeloma

Multiple Myeloma (MM)

Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database

Blood Cancer J

Rajkumar SV, Mateos MV, Schaeffer M, Lin X, Bathija S, Gupta-Werner N, Lam A, Carson R, Dennis R, Kaila S, Matt K, Duran J, Lonial S

doi: 10.1038/s41408-024-01170-z

EHA 2025

Multiple Myeloma (MM)

GMMG-CONCEPT: Isatuximab plus KRd leads to high and sustained MRD negativity in transplant-eligible patients with high-risk NDMM

CHICAGO 2025

Head and Neck Cancer

LBA2: NIVOPOSTOP: Adding nivolumab to adjuvant cisplatin-radiotherapy improves DFS in high-risk patients with LA-SCCHN

ESMO 2025

Genitourinary Cancer

POTOMAC: Durvalumab plus BCG significantly improves DFS in patients with high-risk NMIBC

SABCS 2024

Breast Cancer

OlympiA: Olaparib continues to demonstrate improved OS, IDFS and DDFS in patients with BRCA1/2-mutated HER2-negative high-risk early breast cancer

ESMO 2025

Breast Cancer

monarchE: Adjuvant abemaciclib plus ET significantly improves OS in high-risk HR-positive, HER2-negative early breast cancer

Multiple Myeloma (MM)

High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing

Blood

Schavgoulidze A, Perrot A, Leleu X, Cazaubiel T, Chretien ML, Feugier P, Belhadj K, Manier S, Roussel M, Brechignac S, Orsini Piocelle F, Mohty M, Schiano de Colella JM, Macro M Dr, Adiko D, Dib M, Fontan J, Motard C, Bouscary D, Pascal L, Roland V, Lifermann F, Bakala JA, Montes L, Kennel C, Rey P, Richez V, Keddar F, Frenzel L, Calmettes C, Chaleteix C, Plantier I, Chalayer E, Schmitt A, Roul C, Demarquette H, Cerutti C, Pavageau L, Derrier L, Avet-Loiseau H, Corre J

doi: 10.1182/blood.2025029999

Related content

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis®)-Based Regimens in Patients with NDMM

AQUILA: Daratumumab significantly improves PFS in high-risk smoldering multiple myeloma

Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database

GMMG-CONCEPT: Isatuximab plus KRd leads to high and sustained MRD negativity in transplant-eligible patients with high-risk NDMM

LBA2: NIVOPOSTOP: Adding nivolumab to adjuvant cisplatin-radiotherapy improves DFS in high-risk patients with LA-SCCHN

POTOMAC: Durvalumab plus BCG significantly improves DFS in patients with high-risk NMIBC

OlympiA: Olaparib continues to demonstrate improved OS, IDFS and DDFS in patients with BRCA1/2-mutated HER2-negative high-risk early breast cancer

monarchE: Adjuvant abemaciclib plus ET significantly improves OS in high-risk HR-positive, HER2-negative early breast cancer

High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing

Deep and Sustained Responses with Quadruplet Carfilzomib (Kyprolis^®)-Based Regimens in Patients with NDMM